Literature DB >> 28089051

Individualized Medicine in Ovarian Cancer: Are We There Yet?

Shannon N Westin1, Robert L Coleman2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28089051      PMCID： PMC5881923          DOI： 10.1016/j.ygyno.2017.01.006

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  34 in total

1.  Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).

Authors:  A Spreafico; A M Oza; B A Clarke; H J Mackay; P Shaw; M Butler; N C Dhani; S Lheureux; M K Wilson; S Welch; T Zhang; C Yu; T Stockley; L L Siu; S Kamel-Reid; P L Bedard
Journal:  Gynecol Oncol       Date:  2017-01-03       Impact factor: 5.482

2.  A phase 3 trial of bevacizumab in ovarian cancer.

Authors:  Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

3.  Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas.

Authors:  David S P Tan; Marjan Iravani; W Glenn McCluggage; Maryou B K Lambros; Fernanda Milanezi; Alan Mackay; Charles Gourley; Felipe C Geyer; Radost Vatcheva; Joanne Millar; Karen Thomas; Rachael Natrajan; Kay Savage; Kerry Fenwick; Alistair Williams; Charles Jameson; Mona El-Bahrawy; Martin E Gore; Hani Gabra; Stanley B Kaye; Alan Ashworth; Jorge S Reis-Filho
Journal:  Clin Cancer Res       Date:  2011-03-15       Impact factor: 12.531

4.  Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.

Authors:  Kathleen M Schmeler; Charlotte C Sun; Diane C Bodurka; Michael T Deavers; Anais Malpica; Robert L Coleman; Pedro T Ramirez; David M Gershenson
Journal:  Gynecol Oncol       Date:  2007-12-26       Impact factor: 5.482

5.  K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary.

Authors:  T Enomoto; C M Weghorst; M Inoue; O Tanizawa; J M Rice
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

6.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

Authors:  Robert A Burger; Michael W Sill; Bradley J Monk; Benjamin E Greer; Joel I Sorosky
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

Review 7.  Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.

Authors:  Farbod Shojaei; Napoleone Ferrara
Journal:  Drug Resist Updat       Date:  2008-10-23       Impact factor: 18.500

Review 8.  Mechanisms of resistance to therapies targeting BRCA-mutant cancers.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  Nat Med       Date:  2013-10-07       Impact factor: 53.440

9.  Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.

Authors:  V Abkevich; K M Timms; B T Hennessy; J Potter; M S Carey; L A Meyer; K Smith-McCune; R Broaddus; K H Lu; J Chen; T V Tran; D Williams; D Iliev; S Jammulapati; L M FitzGerald; T Krivak; J A DeLoia; A Gutin; G B Mills; J S Lanchbury
Journal:  Br J Cancer       Date:  2012-10-09       Impact factor: 7.640

Review 10.  New Mechanisms of Tumor-Associated Macrophages on Promoting Tumor Progression: Recent Research Advances and Potential Targets for Tumor Immunotherapy.

Authors:  Qiujun Guo; Zhichao Jin; Yuan Yuan; Rui Liu; Tao Xu; Huamin Wei; Xinyao Xu; Shulin He; Shuntai Chen; Zhan Shi; Wei Hou; Baojin Hua
Journal:  J Immunol Res       Date:  2016-11-16       Impact factor: 4.818
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.